Rondags, Angelique
van Marle, Laura
Horváth, Barbara
Wink, Freke R.
Arends, Suzanne
Spoorenberg, Anneke
Article History
Received: 9 July 2023
Accepted: 18 July 2023
First Online: 9 August 2023
Declarations
:
: The GLAS cohort was approved by the local ethics committees of the Medical Center Leeuwarden (MCL) and the University Medical Center Groningen (UMCG).All patients provided written informed consent according to the Declaration of Helsinki, in which they also gave written permission to be approached (non-committal) for SpA-related research.No additional informed consent was needed for this study according to the local ethical committee.
: Not applicable.
: A.R.—Declarations of interest: none.L.v.M.—Declarations of interest: none.B.H.—Declarations of interest: B. Horváth reports fees from Janssen-Cilag (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), AbbVie (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), Novartis Pharma (Advisory Boards, Consultations, Investigator Initiative Studies), UCB Pharma (Advisory Boards, Consultations), Leo Pharma (Consultations), Solenne B.V. (Investigator Initiative Studies), Celgene (Consultations, Investigator Initiative Studies), Akari therapeutics (Consultations, Investigator Initiative Studies), Philips (Consultation), Roche (Consultation), Regeneron (Consultation) and Sanofi (Consultation), which fees were paid to the institution.F.R.W.—Declarations of interest: none.S.A.—Declarations of interest: none.A.S.—Declarations of interest: A. Spoorenberg reports fees from AbbVie (Advisory Boards, Educational grants, Consultations), Novartis Pharma (Advisory Boards, Consultations, Investigator Initiative Studies), Pfizer (Advisory Boards, Consultations, Investigator Initiative Studies), UCB Pharma (Advisory Boards, Consultations), which fees were paid to the institution.